Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Shigeyuki Suenaga

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3726-5961; OpenAlex author ID A5110550306. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 10

  1. A Novel Index Consisting of Age, CA19-9, and Methylated Somatostatin Is Useful for Diagnosing Early Pancreatic Cancer. Co-author DOI 10.1002/cam4.72202↗
  2. High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation. Co-author DOI 10.1038/s41598-026-56838-2↗
  3. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer. First author DOI 10.1159/000527342↗
  4. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000511940↗
  5. Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. Co-author DOI 10.21873/invivo.11286↗
  6. Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Co-author PMID 24403454↗
  7. Active hexose-correlated compound down-regulates sex-determining region Y-box 2 of pancreatic cancer cells. Co-author PMID 25202061↗
  8. Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells. First author PMID 23898070↗
  9. Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. Co-author PMID 24222118↗
  10. Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Co-author PMID 22641665↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taro Takami · 4 shared papers, 2021–2026 · strength 0.77
  2. Kaori Hamamoto · 3 shared papers, 2022–2026 · strength 0.66
  3. Shuhei Shinoda · 3 shared papers, 2018–2026 · strength 0.64
  4. Yutaka Suehiro · 3 shared papers, 2021–2026 · strength 0.48
  5. Takahiro Yamasaki · 3 shared papers, 2021–2026 · strength 0.48
  6. Isao Sakaida · 7 shared papers, 2012–2022 · strength 0.47
  7. Shin Hamada · 1 shared paper, 2026 · strength 0.29
  8. Atsushi Masamune · 1 shared paper, 2026 · strength 0.29
  9. Masato Yamamoto · 1 shared paper, 2026 · strength 0.29
  10. Shoko Tabara · 1 shared paper, 2026 · strength 0.26
  11. Yuko Fujimoto · 2 shared papers, 2021–2022 · strength 0.23
  12. Hiroto Matsui Matsui · 2 shared papers, 2021–2022 · strength 0.23
  13. Shogo Amano · 2 shared papers, 2018–2022 · strength 0.21
  14. Kazuyuki Nakamura · 5 shared papers, 2012–2014 · strength 0.18
  15. Yasuhiro Kuramitsu · 5 shared papers, 2012–2014 · strength 0.18
  16. Yoshihiko Maehara · 4 shared papers, 2013–2014 · strength 0.15
  17. Yufeng Wang · 4 shared papers, 2012–2014 · strength 0.14
  18. Hiroaki Nagano · 1 shared paper, 2022 · strength 0.12
  19. Keiko Shinjo · 1 shared paper, 2022 · strength 0.12
  20. Yutaka Kondo · 1 shared paper, 2022 · strength 0.12
  21. Hiroaki Nagano · 1 shared paper, 2021 · strength 0.11
  22. Manabu Sen-yo · 1 shared paper, 2018 · strength 0.09
  23. Michitaka Kawano · 1 shared paper, 2018 · strength 0.09
  24. Byron Baron · 2 shared papers, 2013–2014 · strength 0.07
  25. Junya Nawata · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.